Print（PDF/52KB） Mar. 16, 2009 Others
Launch of "PRONAMID",a gastro-prokinetic agent for dogs
Dainippon Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada) launches PRONAMID® tablets, a gastro-prokinetic agent for dogs (generic name: mosapride citrate hydrate) on March 18, 2009, after obtaining a manufacturing and marketing approval as of February 3, 2009.
Mosapride citrate hydrate is one of the company's proprietary compounds, with the efficacy of improving gastrointestinal motility, which has been marketed and sold as an ethical drug for human use under the registered commercial name of GASMOTIN® since 1998. Following the above, the compound has newly been developed for veterinary use under the trade name of PRONAMID®.
The following is the product profile of PRONAMID® :
- It improves gastrointestinal motility by selectively stimulating serotonin 5-HT4 receptor which exists in myenteric nerve plexus located in gastrointestinal tract.
- Unlike other gastro-prokinetic agents, it has no dopamine D2 receptor blocking effect.
- It exhibits excellent efficacy in improving anorexia and vomiting in dog caused by the weakened motility of upper gastrointestines.
PRONAMID® tablets is the first oral agent for veterinary use in Japan that focuses on the improvement of gastrointestinal motility. The company expects that the launch of this product will offer more flexibility in the treatment of dog's gastrointestinal diseases, which are among the major reasons for the animal's hospital visit, and that it will also contribute to the progress of veterinary medicine, bringing about the improvement of diagnostic approaches in the area of dog's digestive system.
At the launch of PRONAMID® tablets, the company plans to hold a series of scientific seminars in five major cities (Sapporo, Tokyo, Nagoya, Osaka and Fukuoka).
The product information of PRONAMID® tablets is outlined in the attachment.
<Attachment for reference>
| [Brand Name] | PRONAMID® |
|---|---|
| [Composition] | PRONAMID® tablet 5mg contains five (5)mg of mosapride citrate. |
| [Indication] | Dog: Improvement in anorexia and vomiting associated with a decrease in motility function of upper gastrointestines (stomach and duodenum) |
| [Dosage and Administration] | 0.25 - 1.0mg of mosapride citrate per kg of body weight orally administered twice a day for 2-4 days |
| [Packaging] | 100 tablets (10 tablets PTP packaging x 10 sheets) |
Inquiries from the Press